Skip to main content
medichelpline
Join Free
Back to Drug Index
General MedicationsORALGeneric

ERYTHROMYCIN

ERYTHROMYCIN

Standard Dose
250MG
Max Dose
Refer to approved labeling
Primary Use
Marketing status: Discontinued

Key Takeaways

  • Primary indication: Marketing status: Discontinued
  • Approval overview ERYTHROMYCIN is listed in Drugs@FDA under application 063098 (ANDA).
  • Marketing status: Discontinued Active ingredient ERYTHROMYCIN Form and strength CAPSULE, DELAYED REL PELLETS;ORAL - 250MG Sponsor BARR Submission history Latest submission status date: 2001-09-27 00:00:00.

Structured Monograph

Clinical summary

Approval overview ERYTHROMYCIN is listed in Drugs@FDA under application 063098 (ANDA). Marketing status: Discontinued Active ingredient ERYTHROMYCIN Form and strength CAPSULE, DELAYED REL PELLETS;ORAL - 250MG Sponsor BARR Submission history Latest submission status date: 2001-09-27 00:00:00. Submission type: SUPPL.

Monitoring

  • • Review priority: STANDARD
  • • Marketing status: Discontinued

Interaction Notes

  • No interaction notes stored yet.